| Prev Close | 94.26 |
| Open | 94.80 |
| Day Low/High | 93.37 / 94.87 |
| 52 Wk Low/High | 74.97 / 96.31 |
| Volume | 3.48M |
| Avg Volume | 2.21M |
Novartis AG (NVS)
93.56
0.70
0.74
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.55B |
| Market Cap | 236.72B |
| EPS | 5.50 |
| P/E Ratio | 17.52 |
| Div & Yield | 1.84 (2.04%) |
Novartis Doesn't Appear Ready to Make Healthy Move Higher
The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning
Happy Friday! These are the stories you must know ahead of the opening bell.
Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.
3 Potential Biotech Buyout Targets in the Second Quarter
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Getting Ready for Biotech Earnings
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Possible Biotech Takeout Plays
A look at possible second-quarter M&A activity in the biotech sector.
Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces
Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.
5 Thing You Must Know Before Monday's Opening Bell
U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.
Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.
There Is Good and a Lot of Bad in General Electric Earnings
John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.
Markets Nicely Off Today's Lows
Markets are down across the board in the first hour of trading. However, we are nicely off the lows of the day. Financials are bucking the early downward tilt of the market and are up today. This sector continues to benefit from slowly rising intere...
What Does CVS's Aetna Acquisition Mean for Amazon?
Is CVS's planned acquisition of Aetna just a reaction to Amazon's dive into healthcare? Here's what we know so far.
How to Manage GE Risk and the Netflix-Disney Fight: Market Recon
Entering GE too early has its costs, but there are ways to mitigate them.
Amazon, Novartis and Netflix - This is What You Need to Know on Tuesday
European markets opened flat as investors await the European Central Bank meeting
European Stocks Euphoria Is Running High ... Maybe Too High
European stock markets are priced almost to perfection ahead of an earnings deluge.
Why I'm Positive on Novartis
Here's where to buy NVS.
Surveying the NASH Drug Landscape
Biotech investors should keep a close eye on the progress in this huge potential market.
Drugmakers Suffer After Trump Tweet
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
Cramer: Money's Being Thrown at Almost Everything in the Market
There are nearly too many surging sectors to count.
Novartis Shows the World a Take of 2 Charts
Novartis has seen some very aggressive buying the past five months -- time to join in.
Biotech Buoyed by Deal Talk
M&A activity is in a serious upswing, and here are some names to watch.
Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks
Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.
Wake Up Wall Street: Positive Earnings Drive Early Trading Higher
Reports from DuPont and Alibaba looked promising for the markets on Wednesday.
News Out of Europe: Intesa Confirms Potential Bid for Generali
News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.
3 Takeover Candidates in the Drug Space
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Prepare for Biotech Action Aplenty Today
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
3 Takeover Candidates in the Drug Space
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Ophthtech Shares Plunge as Drug Fails in Late Stage Trial
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
